Literature DB >> 23039096

Total synthesis and structural revision of lucentamycin A.

Sujeewa Ranatunga1, Chih-Hang Anthony Tang, Chih-Chi Andrew Hu, Juan R Del Valle.   

Abstract

Lucentamycin A is a marine-derived peptide natural product harboring a unique 4-ethylidene-3-methylproline (Emp) subunit. The proposed structure of lucentamycin A and the core Emp residue have recently been called into question through synthesis. Here, we report the first total synthesis of lucentamycin A, which confirms that the ethylidene substituent in Emp bears an E geometry, in contrast to the originally assigned Z configuration. Synthesis of the desired (E)-Emp subunit required the implementation of a novel strategy starting from Garner's aldehyde.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23039096      PMCID: PMC5525334          DOI: 10.1021/jo301723y

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  10 in total

1.  Isolation, structural assignment, and total synthesis of barmumycin.

Authors:  Adriana Lorente; Daniel Pla; Librada M Cañedo; Fernando Albericio; Mercedes Alvarez
Journal:  J Org Chem       Date:  2010-11-23       Impact factor: 4.354

2.  An ester enolate-Claisen rearrangement route to substituted 4-alkylideneprolines. studies toward a definitive structural revision of lucentamycin A.

Authors:  Sujeewa Ranatunga; Jinsoo S Kim; Ujjwal Pal; Juan R Del Valle
Journal:  J Org Chem       Date:  2011-10-05       Impact factor: 4.354

3.  Studies on tomaymycin. I. The structure determination of tomaymycin on the basis of NMR spectra.

Authors:  Z Tozuka; T Takaya
Journal:  J Antibiot (Tokyo)       Date:  1983-02       Impact factor: 2.649

4.  Synthesis of symmetrical trisubstituted olefins by cross metathesis.

Authors:  Arnab K Chatterjee; Daniel P Sanders; Robert H Grubbs
Journal:  Org Lett       Date:  2002-05-30       Impact factor: 6.005

5.  Progress toward the total synthesis of lucentamycin A: total synthesis and biological evaluation of 8-epi-lucentamycin A.

Authors:  R Nathan Daniels; Bruce J Melancon; Emily A Wang; Brenda C Crews; Lawrence J Marnett; Gary A Sulikowski; Craig W Lindsley
Journal:  J Org Chem       Date:  2009-11-20       Impact factor: 4.354

6.  Short, stereoselective synthesis of the naturally occurring pyrrolidine radicamine B and a formal synthesis of nectrisine.

Authors:  Celia Ribes; Eva Falomir; Miguel Carda; J Alberto Marco
Journal:  J Org Chem       Date:  2008-09-03       Impact factor: 4.354

7.  Total synthesis of the putative structure of lucentamycin A.

Authors:  Ujjwal Pal; Sujeewa Ranatunga; Yamuna Ariyarathna; Juan R Del Valle
Journal:  Org Lett       Date:  2009-11-19       Impact factor: 6.005

8.  Lucentamycins A-D, cytotoxic peptides from the marine-derived actinomycete Nocardiopsis lucentensis.

Authors:  Ji Young Cho; Philip G Williams; Hak Chol Kwon; Paul R Jensen; William Fenical
Journal:  J Nat Prod       Date:  2007-07-14       Impact factor: 4.050

9.  Structure assignment of lucentamycin E and revision of the olefin geometries of the marine-derived lucentamycins.

Authors:  Jin Wook Cha; Jin-Soo Park; Taebo Sim; Sang-Jip Nam; Hak Cheol Kwon; Juan R Del Valle; William Fenical
Journal:  J Nat Prod       Date:  2012-09-06       Impact factor: 4.050

10.  Induction of apoptosis in HuH-7 cancer cells by monoterpene and beta-carboline indole alkaloids isolated from the leaves of Tabernaemontana elegans.

Authors:  Tayyab A Mansoor; Rita M Ramalho; Silva Mulhovo; Cecília M P Rodrigues; Maria José U Ferreira
Journal:  Bioorg Med Chem Lett       Date:  2009-05-30       Impact factor: 2.823

  10 in total
  2 in total

Review 1.  Garner's aldehyde as a versatile intermediate in the synthesis of enantiopure natural products.

Authors:  Mikko Passiniemi; Ari Mp Koskinen
Journal:  Beilstein J Org Chem       Date:  2013-11-26       Impact factor: 2.883

Review 2.  A look around the West Indies: The spices of life are secondary metabolites.

Authors:  Adrian Demeritte; William M Wuest
Journal:  Bioorg Med Chem       Date:  2020-10-01       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.